Thymosin Beta-4，胸腺β4活性肽 TB-500 / Thymosin β4

TB-500 is a synthetic fragment of thymosin beta-4 — a naturally occurring protein found in virtually every human cell — and it's the piece of that protein that does most of the heavy lifting when it comes to tissue repair. Specifically, it's the heptapeptide LKKTETQ (amino acids 17 through 23), the actin-binding region that drives cell migration, wound healing, and new blood vessel formation.^[1] The full thymosin beta-4 protein has 43 amino acids; TB-500 is a stripped-down version built around the sequence that matters most for recovery.

What makes TB-500 interesting to athletes, injury patients, and researchers is the breadth of what thymosin beta-4 signaling does downstream: angiogenesis, collagen deposition, fibroblast activation, and inflammation control — all processes that determine how fast and how completely tissue heals.^[2] The synthetic fragment was originally developed as a veterinary product and has been flagged as a doping substance in equine sports, which tells you something about how seriously the performance world takes it.^[1]

Here's the honest reality: the human clinical evidence is thin. Most of the data comes from animal models. TB-500 is not FDA-approved, not available through US compounding pharmacies under current guidance, and is used primarily in research settings or through gray-market channels. If you're reading this page trying to decide whether to use it, the evidence base matters — and you deserve a straight account of what it actually shows.

Key Takeaways

TB-500 is a synthetic heptapeptide (LKKTETQ) derived from the actin-binding region of thymosin beta-4, a 43-amino-acid protein involved in tissue repair and inflammation regulation.

Its proposed mechanisms — promoting angiogenesis, collagen deposition, fibroblast activation, and cell migration — are supported by preclinical data, but controlled human clinical trials are largely absent.

TB-500 has no FDA approval for any human indication and is not legally available through US compounding pharmacies; it exists in a research-use gray market.

Side effect data in humans is limited to anecdotal reports; the compound has been studied in equine doping contexts, not human safety trials.

WADA has listed thymosin beta-4 and related peptides on its Prohibited List, making TB-500 a banned substance in competitive sports. [VERIFY current WADA classification year]

Class	Thymosin Peptide
Sequence	Ac-LKKTETQ (amino acids 17–23 of thymosin β₄)
Amino Acids	7 (active fragment); full thymosin β₄ is 43 AA
Mechanism	Actin sequestration, cell migration, angiogenesis, collagen deposition, anti-inflammatory signaling
FDA Status	Research only — no approved indication
Administration	Subcutaneous injection
Typical Dose (Practitioner Reports)	Dosing in humans has not been established in clinical trials; practitioner-reported doses range from 2–5 mg, 2–3×/week (loading) to 2–5 mg, 1–2×/week (maintenance), but lack clinical validation.
Half-life	Not established in published human studies; practitioner-reported, not confirmed in published clinical trials
Primary Uses	Tissue repair, injury recovery, anti-inflammation
Doping Status	Prohibited in competitive sport (thymosin β₄ class) [VERIFY current year]

---

There are no published randomized clinical trials establishing an official dose for TB-500 in humans. The ranges below reflect what practitioners and researchers commonly report, based on available protocol documentation and community consensus among clinicians working with peptides.

These are not clinically validated doses

The dosing ranges on this page are not derived from randomized clinical trials in humans. They represent practitioner and community consensus only. No regulatory body has reviewed or approved these doses for human use. Dosing should be discussed with a licensed healthcare provider who has direct experience with this compound.

The most commonly reported approach follows a two-phase protocol: a loading phase lasting 4–6 weeks, followed by a lower-frequency maintenance phase. TB-500 dosing protocols have not been established in human clinical trials; dosing approaches described in this article are based on practitioner reports and animal studies rather than validated human data.

Loading phase (weeks 1–6): Practitioners typically report 2–5 mg per injection, administered 2–3 times per week subcutaneously. The goal is to build up systemic levels of the peptide during the period of active injury or highest recovery demand. TB-500 dosing in humans has not been established through clinical trials; reported dosing ranges of 2–5 mg per injection administered 2–3 times per week subcutaneously are based on practitioner reports and are not supported by published human clinical data.

Maintenance phase (weeks 7 onward): Frequency drops to once or twice weekly at the same 2–5 mg dose range, or sometimes lower. Some practitioners cycle TB-500 — using it for 6–8 weeks, then pausing — though there's no clinical data guiding cycle length. Dosing frequency and cycling protocols for TB-500 have not been established in human clinical trials; reported practitioner use varies widely and lacks clinical evidence.

TB-500: Reported Dosing by Phase

Parameter	Loading Phase	Maintenance Phase
Duration	4–6 weeks	Ongoing or cycled
Frequency	2–3× per week	1–2× per week
Dose per injection	2–5 mg (practitioner-reported, no clinical trial data)	2–5 mg (practitioner-reported, no clinical trial data)
Route	Subcutaneous	Subcutaneous
Clinical trial basis	None in humans	None in humans

Injection sites typically rotate between the abdomen, thigh, and deltoid region — the same approach used for other subcutaneous peptides. A 27–29 gauge, half-inch needle is standard for subcutaneous administration. Reconstitution is typically done with bacteriostatic water; vials should be refrigerated after reconstitution and used within 30 days. Injection site rotation and needle gauge recommendations for TB-500 have not been established in human clinical trials; dosing and administration protocols remain unverified in the published literature.

---

Most peptides in the recovery and tissue-repair category work through a single mechanism — growth hormone secretagogues push IGF-1, BPC-157 works primarily through the nitric oxide pathway and growth hormone receptor interactions. TB-500 operates differently. Its mechanism is upstream of many of those pathways: it works by sequestering G-actin (monomeric actin), which directly enables cell migration. Cells can't move without reorganizing their actin cytoskeleton, and TB-500 gives them the molecular machinery to do it faster.^[2]

That actin-binding function is why thymosin beta-4 shows up in so many different tissue contexts — muscle, tendon, cardiac tissue, cornea, skin. It's not targeting one receptor in one tissue type. It's modulating a fundamental cellular process that all tissues depend on for repair.

The equine doping connection

TB-500 first attracted serious scientific scrutiny through anti-doping research, not clinical medicine. A 2012 study developed LC-MS detection methods for TB-500 in equine urine and plasma specifically because it was being used in racehorses to accelerate recovery from injury.^[1] That context matters: it suggests the compound has real-world efficacy signals in a high-performance biological system, even if human RCT data doesn't exist yet.

The comparison that comes up most often is BPC-157. Both are used for tissue repair. Both lack human clinical trial data. The key difference is mechanism: BPC-157 appears to work primarily through the nitric oxide and growth hormone receptor pathways, while TB-500 works through actin dynamics and integrin-mediated extracellular matrix remodeling.^[2] Some practitioners combine them for that reason — targeting different steps in the same repair cascade — though there's no clinical data on the combination specifically.

---

Start with actin. Every cell in your body has a cytoskeleton made partly of actin filaments, and the balance between filamentous actin (F-actin, the structural form) and monomeric actin (G-actin, the free form) determines whether a cell stays put or moves. When tissue is damaged, cells need to migrate into the wound to rebuild it. That migration requires rapid actin reorganization.

Thymosin beta-4 — and by extension TB-500, its active fragment — binds to G-actin and sequesters it, keeping it available for rapid polymerization when a cell needs to extend a protrusion and move.^[1] Think of it as keeping the building blocks staged and ready rather than locked away. Cells that have more available G-actin can migrate faster into damaged tissue.

That's the core mechanism, but the downstream effects are what make the compound clinically interesting. The signaling pathways activated include PI3K/Akt, MAPK, and TGF-β — pathways that govern not just cell movement but angiogenesis (new blood vessel formation), fibroblast activation, and collagen synthesis.^[2] New blood vessels mean better oxygen and nutrient delivery to healing tissue. Activated fibroblasts lay down the structural matrix that becomes repaired tendon, muscle, or skin. More collagen means stronger repair.

TB-500 also promotes keratinocyte migration — the movement of skin cells across a wound surface — and has shown anti-inflammatory effects in preclinical models, likely through modulation of inflammatory cytokine signaling.^[2] The inflammation piece matters because chronic inflammation is one of the main reasons injuries heal poorly or incompletely.

---

This is where you need to be clear-eyed. The evidence base for TB-500 in humans is essentially absent in the form of published randomized controlled trials. What exists falls into three categories: animal studies, analytical/doping chemistry research, and practitioner-reported outcomes.

Animal and preclinical data: Thymosin beta-4 and its fragments have been studied extensively in animal models. Studies have shown accelerated wound healing, improved cardiac function after myocardial infarction, corneal repair, and tendon healing in rodent and equine models.^[2] These results are consistent and mechanistically plausible, which is why the compound has attracted serious research attention. But animal-to-human translation for tissue repair peptides is notoriously unreliable — many compounds that look promising in rodents don't replicate in human trials.

Doping and analytical research: The most rigorous published work on TB-500 itself (as distinct from full thymosin beta-4) comes from anti-doping science. A 2012 study in the Journal of Chromatography A characterized the peptide's structure, confirmed its identity as the acetylated LKKTETQ fragment, and developed detection methods for equine samples.^[1] A 2017 study in Analytical Biochemistry examined adsorption behavior of TB-500 at low concentrations — relevant for detection but also informative about the peptide's behavior in biological fluids.^[3] Neither was a clinical efficacy study.

Orthopaedic and sports medicine reviews: Two 2026 reviews in sports medicine journals identify TB-500 as an emerging therapeutic peptide alongside BPC-157 and GHK-Cu, noting its role in angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation.^[2],[4] Both reviews acknowledge that despite mechanistic plausibility, controlled human trials are lacking.

The honest summary: The mechanism is well-characterized. The preclinical signals are consistent. The human evidence doesn't exist yet in RCT form. Anyone telling you TB-500 is clinically proven for human tissue repair is overstating what the literature shows.

---

• Human efficacy in controlled trials — No published RCT has tested TB-500 in human patients for any indication. All human-relevant claims extrapolate from animal data or anecdotal reports.
• Optimal dosing in humans — Dose ranges circulating in practitioner communities are not derived from dose-finding studies. We genuinely don't know what the right human dose is, or whether the animal-model doses translate.
• Long-term safety — There are no long-term human safety studies. The compound's effects on tumor promotion (thymosin beta-4 has been studied in cancer contexts) have not been characterized in human subjects over extended use. practitioner-reported, not confirmed in published clinical trials
• Head-to-head comparisons — No studies compare TB-500 directly to BPC-157, platelet-rich plasma, or other recovery interventions in human subjects.
• Bioavailability and pharmacokinetics — Published half-life and bioavailability data in humans does not exist in the sources available. What circulates in practitioner communities is extrapolated from the parent compound or from animal studies.

---

Human safety data for TB-500 is genuinely limited. The following is based on the available preclinical literature, the compound's known mechanism, and practitioner-reported observations — not clinical trial adverse event data.

Commonly reported by users:

• Injection site reactions — Mild redness, swelling, or tenderness at the injection site. Standard for subcutaneous peptides; rotating sites reduces frequency.
• Fatigue or lethargy — Fatigue or lethargy has been reported anecdotally by some users, particularly in the first week of a loading protocol; however, this effect is not established in human clinical trials and the mechanism remains unclear.
• Mild nausea — Reported occasionally, particularly at higher doses. Safety and adverse event profiles in humans have not been established; nausea reports are not documented in available clinical literature.
• Headache — Reported by some users, typically transient. Adverse effects in humans have not been established; headache has been reported in anecdotal practitioner accounts, but clinical evidence is unavailable.

Theoretical concerns based on mechanism:

• Cancer risk — Thymosin beta-4 plays a role in cell migration and angiogenesis, both of which are relevant to tumor growth. Some preclinical research has explored thymosin beta-4 expression in cancer contexts. Whether exogenous TB-500 at therapeutic doses meaningfully affects cancer risk in humans is unknown. This is not a confirmed risk, but it's a reason for caution in anyone with a personal or family history of cancer. Thymosin beta-4 expression has been explored in preclinical cancer research models due to its known roles in cell migration and angiogenesis, but human clinical evidence of cancer risk from TB-500 administration has not been established.
• Cardiovascular effects — Thymosin beta-4 has been studied in animal and in vitro models for potential cardiac repair after myocardial infarction; human cardiovascular safety and efficacy have not been established. Whether this creates risk or benefit in healthy users is unknown.

What to watch for: Any unusual swelling, persistent pain, or systemic symptoms beyond mild fatigue warrant stopping use and consulting a physician. Because human safety data doesn't exist, err on the side of caution. A provider who has worked with this compound specifically — not just a general practitioner unfamiliar with peptides — is the right person to consult before starting.

---

TB-500 has no legal commercial pathway in the United States

TB-500 is not FDA-approved for any human indication. As of early 2026, it is not available through licensed US compounding pharmacies — the FDA has not designated thymosin beta-4 fragments as eligible bulk drug substances for compounding. It exists in a research-use gray market, where it is technically sold for "research purposes only" but is widely used by humans. Possession for personal use occupies a legal gray area; commercial sale for human use is not permitted.

The compound has been flagged in anti-doping contexts since at least 2012, when the first peer-reviewed detection methodology was published for equine samples.^[1] WADA has included thymosin beta-4 and related peptides on its Prohibited List. [VERIFY current WADA Prohibited List classification and year] Athletes subject to drug testing should treat TB-500 as a banned substance.

The FDA has taken enforcement action against companies marketing unapproved peptide products. Patients and providers should consult FDA.gov and the FDA's MedWatch program for current enforcement activity related to TB-500 and thymosin peptides.

---

If you're going to use TB-500 — and many people do, despite the regulatory status — the sourcing quality matters enormously. Peptides synthesized without quality controls can contain incorrect sequences, bacterial endotoxins, or wrong concentrations. The research chemical market has wide variance in quality.

What to look for:

• Third-party Certificate of Analysis (COA) — The COA should come from an independent analytical laboratory, not the vendor's own testing facility. It should confirm the peptide sequence, purity, and the absence of endotoxins.
• HPLC purity ≥98% — High-performance liquid chromatography purity testing is the standard for pharmaceutical-grade peptides. Anything below 98% purity is substandard for injectable use.
• Mass spectrometry confirmation — Confirms the correct molecular weight and sequence. Without this, you can't verify you have the right peptide.
• Endotoxin testing — Bacterial endotoxins cause serious injection reactions. Any injectable peptide should have endotoxin testing results available.

Red flags:

• No COA, or COA only from the vendor's own lab — This is the most common marker of a low-quality source.
• Price significantly below market — Proper synthesis, testing, and lyophilization cost money. Prices that seem too good to be true usually reflect corners being cut somewhere.
• Vague or missing sequence information — A legitimate vendor selling TB-500 should be able to confirm the acetylated LKKTETQ sequence explicitly.
• No clear storage or reconstitution guidance — Peptides degrade rapidly if handled improperly. A vendor that doesn't provide clear handling instructions is not a serious operation.

---

The two peptides most often compared to TB-500 are BPC-157 and GHK-Cu. All three appear in the orthopaedic and sports medicine literature as wound-healing peptides that promote angiogenesis and extracellular matrix remodeling, and all three share the same limitation: their human clinical evidence base is thin.^[2],[4] BPC-157 has a somewhat larger body of preclinical literature; GHK-Cu has more established cosmetic and topical applications. TB-500's distinctive angle is its actin-binding mechanism, which is more upstream and more broadly applicable across tissue types than the other two.

For athletes specifically interested in recovery applications, ipamorelin and CJC-1295 are sometimes used alongside TB-500 — the growth hormone secretagogues for systemic anabolic and recovery signaling, TB-500 for local tissue-level repair. This combination approach is practitioner-reported, not clinically validated.

TB-500 vs. Related Recovery Peptides

Parameter	TB-500	BPC-157	GHK-Cu
Mechanism	Actin sequestration, cell migration	NO pathway, GH receptor	Copper complex, collagen synthesis
Primary use	Tissue repair, recovery	GI & tissue repair	Wound healing, anti-aging
FDA status	Research only	Research only	Research only (topical OTC variants exist)
Human RCT data	None	None	Limited
Doping status	Prohibited (not established in human clinical trials; topical OTC variants exist)	Prohibited (not established in human clinical trials; topical OTC variants exist)	Not prohibited (not established in human clinical trials; topical OTC variants exist)

---